The coagulopathy in acute promyelocytic leukaemia - What have we learned in the past twenty years

Hau C. Kwaan*, Elizabeth H. Cull

*Corresponding author for this work

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

Coagulopathy is a unique component of the pathology of acute promyelocytic leukaemia (APL). Though many causative factors have been elucidated, therapies to rectify the coagulopathy are far from being realised. Thrombotic and bleeding complications remain the major causes of early deaths. In this chapter, the known causes of abnormalities in haemostatic function, namely the coagulopathy and changes in the fibrinolytic system, will be reviewed. Major risk factors for these complications are identified. Current available measures for correction of the coagulopathy and their effectiveness are critically examined. Unless the coagulopathy can be effectively controlled, bleeding complications will remain an obstacle to achieving a cure for this disease. The issues that need to be addressed in next phase of investigations are also discussed.

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalBest Practice and Research: Clinical Haematology
Volume27
Issue number1
DOIs
StatePublished - Mar 2014

Keywords

  • acute promyelocytic leukaemia
  • bleeding
  • fibrinolysis
  • thrombosis
  • tissue factor

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'The coagulopathy in acute promyelocytic leukaemia - What have we learned in the past twenty years'. Together they form a unique fingerprint.

  • Cite this